Cutler Group’s Caribou Biosciences CRBU Stock Holding History

Cutler Group’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	–	–	2482
2023 Q4	$0	Buy	+100	New	+$494	﹤0.01%	3705
2022 Q3	–	Sell	-5,053	Closed	-$27K	–	4987
2022 Q2	$27K	Buy	+5,053	New	+$38.6K	﹤0.01%	2429

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cutler Group's CRBU Position: Q1 2024 in Review

Cutler Group sold out of Caribou Biosciences (CRBU) in Q1 2024, closing a stake of 100 shares.

Cutler Group first reported a position in CRBU in Q2 2022 and held it in 2 quarters. The position peaked at $27K in Q2 2022. 151 funds tracked by Wall St. Rank hold CRBU as of Q1 2024.

Cutler Group reported no remaining Caribou Biosciences position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 100 Caribou Biosciences shares in Q1 2024.
Cutler Group first reported a position in Caribou Biosciences in Q2 2022 and held it in 2 quarters.
Cutler Group's Caribou Biosciences position peaked at $27K in Q2 2022.
151 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.